The Potential for microRNA Therapeutics and Clinical Research

As FDA-approved small RNA drugs start to enter clinical medicine, ongoing studies for the microRNA (miRNA) class of small RNAs expand its preclinical and clinical research applications. A growing number of reports suggest a significant utility of miRNAs as biomarkers for pathogenic conditions, modul...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Frontiers in genetics Ročník 10; s. 478
Hlavní autoři: Hanna, Johora, Hossain, Gazi S., Kocerha, Jannet
Médium: Journal Article
Jazyk:angličtina
Vydáno: Switzerland Frontiers Media S.A 16.05.2019
Témata:
clinical trials
epigenetic
Genetics
microRNAs
ncRNA
noncoding RNA
preclinical
microRNAs
noncoding RNA
clinical research
epigenetic
preclinical
clinical trials
ncRNA
ISSN:1664-8021, 1664-8021
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:As FDA-approved small RNA drugs start to enter clinical medicine, ongoing studies for the microRNA (miRNA) class of small RNAs expand its preclinical and clinical research applications. A growing number of reports suggest a significant utility of miRNAs as biomarkers for pathogenic conditions, modulators of drug resistance, and/or as drugs for medical intervention in almost all human health conditions. The pleiotropic nature of this class of nonprotein-coding RNAs makes them particularly attractive drug targets for diseases with a multifactorial origin and no current effective treatments. As candidate miRNAs begin to proceed toward initiation and completion of potential phase 3 and 4 trials in the future, the landscape of both diagnostic and interventional medicine will arguably continue to evolve. In this mini-review, we discuss miRNA drug discovery development and their current status in clinical trials.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: George Calin, University of Texas MD Anderson Cancer Center, United States; Peter Igaz, Semmelweis University, Hungary
This article was submitted to RNA, a section of the journal Frontiers in Genetics
Edited by: Rami I. Aqeilan, Hadassah Medical Center, Israel
ISSN:1664-8021
1664-8021
DOI:10.3389/fgene.2019.00478